Weston-based Biogen Idec Inc. said Tuesday that European Union regulators have approved an injectable pen version of Avonex, its popular multiple sclerosis drug.
NEW YORK (AP) — The Weston-based biotechnology firm, Biogen Idec Inc., said Tuesday that European Union regulators approved an injectable pen version of Avonex, its popular multiple sclerosis drug.
The Avonex Pen is approved for patients who have experienced the first symptoms of MS, or who have the relapsing form of the disease. The pens are single-use pens with a dose that lasts one week. Biogen Idec said it will start making the pens available in Europe over the next few weeks.
Avonex is the biotech company's biggest-selling drug. Worldwide sales of Avonex totaled $2.52 billion in 2010.